Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients

Matteelli, Alberto; Regazzi, Mario; Villani, Paola; De Iaco, Giuseppina; Cusato, Maria; Carvalho, Anna Cristina C.; Caligaris, Silvio; Tomasoni, Lina; Manfrin, Maria; Capone, Susanna; Carosi, Giampiero
May 2007
Current HIV Research;Jul2007, Vol. 5 Issue 3, p349
Academic Journal
Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/�l and 5.2 /�l, respectively. Cases had a significantly higher Cl/F/kg if compared with controls (0.269 � 0.12 versus 0.167 + 0.05 L/h/kg, p<0.01). Otherwise, dose-dependent pharmacokinetic parameters of EFV were similar between cases and controls. Interindividual variability was consistently higher among TB cases compared to controls for all considered parameters. All cases completed combined treatment and no increased EFV toxicity was observed. These results suggest that a dose of 800 mg of EFV in association with rifampicin may be appropriate for patients of weight > 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.


Related Articles

  • Clinical and radiological deterioration in a patient with AIDS. De Backer, A. I.; Mortelé, K. J.; Bomans, P.; De Keulenaer, B. L.; Vanschoubroeck, I. J.; Kockx, M. M.; Mortelé, K J // European Radiology;Nov2005, Vol. 15 Issue 11, p2264 

    Paradoxical clinical deterioration of miliary tuberculosis, characterized by pulmonary and abdominal manifestations, is reported in a patient with the acquired immunodeficiency syndrome, after initiation of treatment with highly active antiretroviral therapy. Paradoxical reaction was attributed...

  • Determinants of Immune Reconstitution Inflammatory Syndrome in HIV Type 1-Infected Patients with Tuberculosis after Initiation of Antiretroviral Therapy. Breton, Guillaume; Duval, Xavier; Estellat, Candice; Poaletti, Xavier; Bonnet, Daniel; Mvondo, David Mvondo; Longuet, Pascale; Leport, Catherine; Vildé, Jean-Louis // Clinical Infectious Diseases;12/1/2004, Vol. 39 Issue 11, p1709 

    Immune reconstitution inflammatory syndrome (IRIS) occurred in 16 of 37 antiretroviral-naive patients who were treated subsequently for tuberculosis and human immuno-deficiency virus (H IV) type 1 infection. IRIS was related to increases in the CD4 cell percentage and in the ratio of CD4 cells...

  • Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in India. Padmapriyadarsini, Chandrasekaran; Kumar, S. Ramesh; Terrin, Norma; Narendran, Gopalan; Menon, Pradeep A.; Ramachandran, Geetha; Subramanyan, Sudha; Venkatesan, Perumal; Wanke, Christine; Swaminathan, Soumya // Clinical Infectious Diseases;2/15/2011, Vol. 52 Issue 4, p540 

    Background. Our aim was to study the incidence and pattern of dyslipidemia among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) who received once-daily antiretroviral therapy (ART). Methods. Antiretroviral-naive HIV-infected patients with TB were recruited to a trial...

  • Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Elsherbiny, Doaa; Cohen, Karen; Jansson, Britt; Smith, Peter; McIlleron, Helen; Simonsson, Ulrika S. H. // European Journal of Clinical Pharmacology;Jan2009, Vol. 65 Issue 1, p71 

    The aim was to develop a model to describe the population pharmacokinetics of nevirapine in South African human immunodeficiency virus (HIV)-infected patients who were taking nevirapine-based antiretroviral therapy concomitantly or in the absence of rifampicin-based tuberculosis therapy....

  • Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria. Aliyu, Gambo; El-Kamary, Samer S.; Abimiku, Alash'le; Ezati, Nicholas; Mosunmola, Iwakun; Hungerford, Laura; Brown, Clayton; Tracy, Kathleen J.; Obasanya, Joshua; Blattner, William // Tuberculosis Research & Treatment;2013, p1 

    Objective. Data on pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) complex in Nigeria are limited. We investigated species of MTB complex in TB cases from northern Nigeria. Methods. New TB suspects were enrolled, screened for HIV and their sputum samples were cultured...

  • Barriers to Initiation of Antiretrovirals during Antituberculosis Therapy in Africa. Pepper, Dominique J.; Marais, Suzaan; Wilkinson, Robert J.; Bhaijee, Feriyl; De Azevedo, Virginia; Meintjes, Graeme // PLoS ONE;2011, Vol. 6 Issue 5, p1 

    Background: In the developing world, the principal cause of death among HIV-infected patients is tuberculosis (TB). The initiation of antiretroviral therapy (ART) during TB therapy significantly improves survival, however it is not known which barriers prevent eligible TB patients from...

  • Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Levine, Beth; Chaisson, Richard E.; Levine, B; Chaisson, R E // Annals of Internal Medicine;5/15/91, Vol. 114 Issue 10, p861 

    Objective: To assess the clinical features and response to therapy of Mycobacterium kansasii infection in patients with human immunodeficiency virus (HIV) infection.Design: We reviewed the records of all patients with M. kansasii and HIV infection treated between...

  • Incidence, risk factors and mortality of tuberculosis in Danish HIV patients 1995-2007. Taarnhøj, Gry A.; Engsig, Frederik N.; Ravn, Pernille; Johansen, Isik S.; Larsen, Carsten S.; Røge, Birgit; Andersen, Aase B.; Obel, Niels // BMC Pulmonary Medicine;2011, Vol. 11 Issue 1, p26 

    Background: Human Immunodeficiency Virus (HIV) infection predisposes to tuberculosis (TB). We described incidence, risk factors and prognosis of TB in HIV-1 infected patients during pre (1995-1996), early (1997-1999), and late Highly Active Antiretroviral Therapy (HAART) (2000-2007) periods....

  • Clinical and laboratory observations of tuberculosis at a Mumbai (India) clinic. Gothi D; Joshi J M; Gothi, D; Joshi, J M // Postgraduate Medical Journal;Feb2004, Vol. 80 Issue 940, p97 

    Objectives: To study the positivity of sputum acid fast bacilli (AFB) smears in patients with pulmonary tuberculosis using 24 hour sputum collection. To detect HIV seropositivity in patients suffering from tuberculosis, and to analyse the pattern of tuberculosis disease in this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics